Indication
Alopecia
14 clinical trials
16 products
Product
EQ101Clinical trial
A 6-month Phase 3, Multicenter, Prospective, Randomized, Double-Blind, Vehicle-Controlled Study, to Evaluate the Efficacy and Safety of Topically Applied Clascoterone Solution for the Treatment of Androgenetic Alopecia in Males, Followed by a 6-month Single-Blind Treatment With Clascoterone or Vehicle SolutionStatus: Recruiting, Estimated PCD: 2024-06-01
Product
ClascoteroneProduct
VehicleClinical trial
An Open-label, Phase 2 Study to Assess the Safety and Efficacy of EQ101 in Adult Subjects With Moderate to Severe Alopecia AreataStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
A Randomized, Double-blind, Vehicle-controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of TDM-105795 in Male Subjects With Androgenetic AlopeciaStatus: Completed, Estimated PCD: 2023-11-08
Product
TDM-105795Clinical trial
A 6-month Phase 3, Multicenter, Prospective, Randomized, Double-Blind, Vehicle-Controlled Study, to Evaluate the Efficacy and Safety of Topically Applied Clascoterone Solution for the Treatment of Androgenetic Alopecia in Males, Followed by a 6-month Single-Blind Treatment With Clascoterone or Vehicle SolutionStatus: Recruiting, Estimated PCD: 2024-08-01
Product
Vehicle solutionClinical trial
A Randomized, Open-label, Multiple-dose and Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A in Male SubjectsStatus: Completed, Estimated PCD: 2023-09-15
Product
CKD-843Product
CKD-843-RProduct
BaricitinibClinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia AreataStatus: Recruiting, Estimated PCD: 2025-04-09
Product
PlaceboClinical trial
Phase IV, National, Unicentric, Comparative, Double-Blind, Randomized, Non- Inferiority Clinical Trial to Evaluate the Efficacy and Safety of DNN.22.17.036 Compared to 10573048700 in the Treatment of Androgenetic AlopeciaStatus: Not yet recruiting, Estimated PCD: 2025-05-01
Product
DNN.22.17.036Product
10573048700Clinical trial
A Randomized, Double Blind, Parallel-group Study to Evaluate the Efficacy and Safety of a New Pharmaceutical Form Minoxidil 5% for the Treatment of Androgenetic Alopecia in Men for 24 WeeksStatus: Active (not recruiting), Estimated PCD: 2024-03-06
Product
MinoxidilClinical trial
Study to Investigate the Effectiveness of a Topical Cosmetic Formulation DA-OTC-002Status: Completed, Estimated PCD: 2023-01-02
Product
DA-OTC-002Clinical trial
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TDM-105795 in Healthy Male Subjects With Androgenetic Alopecia (AGA)Status: Completed, Estimated PCD: 2022-11-15
Product
KX- 826Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study in Male Subjects With Androgenetic Alopecia to Evaluate the Efficacy, Safety, and Tolerability of KX-826 Following Topical Multiple Dose AdministrationStatus: Completed, Estimated PCD: 2023-02-13
Product
KX-826Clinical trial
A Pilot Study of Oral Minoxidil for the Treatment of Persistent Hair Loss in Pediatric, Adolescent, and Young Adult Cancer SurvivorsStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of KX-826 Tincture for Topical Use in Chinese Adult Female Patients With Androgenetic Alopecia (AGA)Status: Completed, Estimated PCD: 2022-11-10
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase Ⅰ Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of GT20029 Gel and Solution for Single and Multi Dose External Administration in Healthy SubjectsStatus: Completed, Estimated PCD: 2022-08-15
Product
GT20029